HIV 1&2 Tests

Atomo offers the world’s first integrated, blood-based rapid diagnostic test (RDT) for HIV screening. Recognized globally for innovative design, performance and ease-of-use. With 99.6% specificity, 99.6% sensitivity, low blood volume and a 24 month shelf life, this test could save 40,000 lives per year in Africa alone.

Atomo HIV Self-Test

The only HIV Self Test listed on the Australian Register of Therapeutic Goods 311989.

AtomoRapid™ HIV 1&2

Ideally suited for point of care testing, Atomo HIV tests for professional use need only 10uL of capillary blood, and gives an accurate result in just 15 minutes.

Simplitude ByMe

Designed & Manufactured by Atomo; Branded & Distributed by Owen Mumford
Distributed in the UK and Europe

Mylan HIV Self-Test

Designed & Manufactured by Atomo; Branded & Distributed by Viatris Inc.
Sold in lower and middle income markets

I-Test HIV Self-Test

Designed, Manufactured by Atomo; Branded and distributed by Iyeza Health
Sold in private sector markets in South Africa, Swaziland, Lesotho and Mozambique

Finished rapid test products are commercialized under Atomo's own brand or under private labels via partners and regional distributors. We hold regulatory approvals including CE Mark in the EU/ UK, Australian TGA, and the World Health Organization with FDA approvals pending.

Develop Future Tests With Us

Atomo’s unique technology presents an opportunity to improve existing products on the market with superior usability. Our integrated platforms can help users easily perform the tests on their own and improve performance, speed and reliability in a professional clinical setting.

We welcome dialogue with forward-thinking diagnostic partners who would like to explore co-developing tests for infectious diseases, allergy sensitivities, women’s health, men’s health, sexual health, heart health and other applications.

Re-imagining diagnostics.